Lee Biosolutions Announces Availability of Eosinophil Cationic Protein

September 7, 2006; ST. LOUIS – Eosinophil cationic protein derived from human neutrophils is now available to the clinical research community from Lee Biosolutions, at LeeBio.com.

Eosinophils are granulocytes that commonly increase in number in the presence of parasites and allergies. Clinical researchers continue to explore methods for using Eosinophil in the pathogenesis of a variety of illnesses, including respiratory conditions such as asthma, nasal polyposis and allergic rhinitis.

According to Lee Biosolutions President Burton Lee, the company plans to also have a polyclonal eosinophil cationic protein antibody available for Fall 2006.

“We are expanding our product line almost daily to meet today’s needs and tomorrow’s trends in research,” Lee said. “We strive to anticipate customers’ needs ahead of time so when they’re ready, we can provide the products they need as a source they already trust for purity and consistency.”

Eosinophils comprise roughly 1% to 4% of the blood’s cellular make-up. The cells are active in allergic diseases, parasitic infections, and other disorders.

For over 30 years, Lee Biosolutions has been providing proteins, enzymes and other materials to research facilities around the country that work to advance the healthcare industry. By providing Solutions on Demand, Lee Biosolutions has become the preferred source for materials such as myeloperoxidase (MPO) and renin.

Lee Biosolutions has become a leader in the biomaterials industry by providing the high quality products to clinical labs and researchers around the world, developing tomorrow’s cures. For more information or to place an order, contact Lee Biosolutions at 314-968-1091, or visit the company’s newly redesigned website, www.leebio.com.